Literature DB >> 8193522

Effect of antihypertensive formulation on health service expenditures.

D A Sclar1, T L Skaer, L M Robison, A Chin, M P Okamoto, R K Nakahiro, M A Gill.   

Abstract

A major barrier to the management of hypertension is the extent to which patients comply with the treatment regimen. Herein we report the findings of a retrospective analysis designed to discern the relationship between antihypertensive formulation, regimen compliance and the utilization of health care services. Data for this analysis were derived from the state of South Carolina's Medicaid computer archive. The study population consisted of 1,000 randomly selected beneficiaries initially prescribed one of the following antihypertensive regimens as monotherapy: atenolol (daily); captopril (twice daily); oral clonidine (twice daily); transdermal clonidine (once a week); diltiazem (twice daily); enalapril (twice daily); metoprolol (twice daily); prazosin (twice daily); terazosin (daily); and verapamil-SR (daily). Multivariate regression analysis was used to determine the incremental influence of selected demographic characteristics, utilization of medical services prior to diagnosis for hypertension, initial antihypertensive medication, medication possession ratio for antihypertensive therapy, and the number of maintenance medications for disease state processes other than hypertension on post-period health care expenditure. Results indicate that patients initially prescribed antihypertensive medication requiring daily or weekly administration experience infrequent changes in their therapeutic regimen, far less use of concomitant therapy for blood pressure control, an increased utilization of antihypertensive medication, and a decrease in the use and cost of physician, hospital and laboratory services.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8193522     DOI: 10.1007/bf01829454

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  23 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

2.  Utility of a transdermal delivery system for antihypertensive therapy. Part 2.

Authors:  D A Sclar; T L Skaer; A Chin; M P Okamoto; M A Gill
Journal:  Am J Med       Date:  1991-07-18       Impact factor: 4.965

Review 3.  Clinical care of the aging hypertensive patient.

Authors:  M L Tuck
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

4.  Clinical acceptability of transdermal clonidine: a large-scale evaluation by practitioners.

Authors:  J Hollifield
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

5.  Efficacy of clonidine as transdermal therapeutic system: the international clinical trial experience.

Authors:  D T Lowenthal; S Saris; E Paran; N Cristal; K Sharif; C Bies; T Fagan
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

6.  Perspectives on systolic hypertension. The Framingham study.

Authors:  W B Kannel; T R Dawber; D L McGee
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

7.  Improved compliance measures: applications in an ambulatory hypertensive drug trial.

Authors:  P Rudd; S Ahmed; V Zachary; C Barton; D Bonduelle
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

8.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

9.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

10.  Detection, evaluation, and treatment of renovascular hypertension. Final report. Working Group on Renovascular Hypertension.

Authors: 
Journal:  Arch Intern Med       Date:  1987-05
View more
  2 in total

1.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence.

Authors:  Leon Dupclay; Michael Eaddy; James Jackson; Aditya Raju; Andrew Shim
Journal:  Patient Prefer Adherence       Date:  2012-07-18       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.